GlassScriptPhysician profile
Natalya Rukhman
NPI 1063616506
$7,065.55
in general payments reported to CMS, 2019-2025
45 companies · $1,954 in 2025
The $1,954 reported for 2025 was more than what 76% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $788 · 2020: $404 · 2021: $1,008 · 2022: $553 · 2023: $888 · 2024: $1,470 · 2025: $1,954.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,312.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,312.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,130.57 | 2019-2025 | Freestyle Libre 3, Eterna |
| Novo Nordisk INC | $742.97 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Dexcom, INC. | $688.81 | 2019-2025 | Dexcom G6 Transmitter |
| Lilly USA, LLC | $421.20 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Sequel Med Tech, LLC | $343.25 | 2025 | Twiist |
| Amgen INC. | $295.95 | 2019-2025 | Evenity, Prolia, Repatha |
| Medtronic Minimed, INC. | $281.16 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $228.98 | 2023-2025 | |
| Sanofi-Aventis U.S. LLC | $225.68 | 2019-2025 | |
| Xeris Pharmaceuticals, INC. | $218.56 | 2021-2025 | Recorlev, Gvoke Hypopen |
| Abbvie INC. | $188.58 | 2019-2025 | |
| Medtronic, INC. | $171.13 | 2023-2025 | Minimed 780g, Vanta Adaptivestim |
| Boehringer Ingelheim Pharmaceuticals, INC. | $159.83 | 2019-2024 | Jardiance, Synjardy, Tradjenta |
| Radius Health, INC. | $156.27 | 2019-2025 | Tymlos |
| Recordati_rare_diseases_inc. | $151.93 | 2023-2025 | Isturisa, Signifor Lar |
Show all 45 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $138.15 | 2020-2025 | Korlym |
| Bayer Healthcare Pharmaceuticals INC. | $137.90 | 2021-2025 | |
| Amarin Pharma, INC. | $116.14 | 2021 | |
| Alexion Pharmaceuticals, INC. | $104.34 | 2024-2025 | Strensiq |
| Lifescan, INC. | $92.01 | 2019-2021 | |
| Antares Pharma, INC. | $90.09 | 2019-2025 | Xyosted |
| Verity Pharmaceuticals INC. | $83.05 | 2024-2025 | Tlando |
| Mannkind Corporation | $77.89 | 2024-2025 | |
| Tandem Diabetes Care, INC. | $76.70 | 2024-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Ibsa Pharma INC. | $71.24 | 2023-2025 | Tirosint, Licart, Tirosint |
| Almatica Pharma LLC | $70.15 | 2024-2025 | Teriparatide |
| Madrigal Pharmaceuticals | $69.77 | 2025 | Rezdiffra |
| Averitas Pharma INC. | $61.09 | 2024 | Qutenza |
| Beta Bionics, INC. | $56.69 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Merck Sharp & Dohme LLC | $49.76 | 2019-2023 | Steglatro, Januvia |
| Astrazeneca Pharmaceuticals LP | $45.40 | 2020-2021 | |
| Amryt Pharma Holdings LTD | $37.39 | 2020-2021 | |
| Insulet Corporation | $31.57 | 2019-2021 | |
| Nevro Corp. | $31.07 | 2023 | Senza |
| Chiesi USA, INC. | $27.55 | 2024 | Mycapssa |
| Ascendis Pharma Endocrinology INC | $24.83 | 2025 | Yorvipath |
| Acella Pharmaceuticals, LLC | $24.34 | 2025 | NP Thyroid 60 |
| Esperion Therapeutics, INC. | $22.97 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $22.41 | 2021 | |
| Ascensia Diabetes Care US INC. | $20.62 | 2021 | |
| Amphastar Pharmaceuticals, INC. | $17.90 | 2025 | |
| Kyowa Kirin, INC. | $17.47 | 2024 | Crysvita |
| Regeneron Healthcare Solutions, INC. | $15.54 | 2019 | |
| Amneal Pharmaceuticals LLC | $13.72 | 2021 | |
| Janssen Pharmaceuticals, INC | $12.93 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Natalya Rukhman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.